Skip to content
Shuttingdown

Cidara Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SAN DIEGO

No longer listed

High confidence (85%)

Updated Oct 9, 2026, 12:05 AM

What is happening

Derived by rule set status-rules-2026.09.7

The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

Latest material event: Cidara Therapeutics, Inc. deregistered its securities (Jan 20, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Cidara Therapeutics, Inc. deregistered its securities

    Jan 20, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 d56540d1512g.htm 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36912 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 (858) 752-6170 (Address, including zip code, and telephone number, including area code…”

  2. Cidara Therapeutics, Inc. was delisted from its exchange

    Jan 7, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001610618 Cidara Therapeutics, Inc. 001-36912 6310 Nancy Ridge Drive, Suite 101 San Diego CA CALIFORNIA 92121 (858) 752-6170 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta Director 2026-01-07”

  3. Cidara Therapeutics, Inc. received a delisting notice from its exchange

    Jan 7, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information contained in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01. In connection with the closing of the Merger, the Company (i) notified The Nasdaq Stock Market LLC ( Nasdaq ) that the Merger was consummated and (ii) requested that Nasdaq (A) halt trading of and delist the Common Shares effective before the opening of trading on January 7, 2026, and (B) file with the SEC a Form 25 Notification of Remo…”

Company information

Founded
—
Employees (estimate)
—
Industry
Biological Products, (No Diagnostic Substances)
Subindustry
—
SEC CIK
0001610618
Website
—
LinkedIn
—
Headquarters
SAN DIEGO
Also known as
K2 THERAPEUTICS, INC.
Legal entities
Cidara Therapeutics, Inc.

Sources

Every material source used to build this profile.

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Cidara Therapeutics, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — SAN DIEGO, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 d56540d1512g.htm 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36912 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 (858) 752-6170 (Address, including zip code, and telephone number, including area code…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001610618 Cidara Therapeutics, Inc. 001-36912 6310 Nancy Ridge Drive, Suite 101 San Diego CA CALIFORNIA 92121 (858) 752-6170 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta Director 2026-01-07
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information contained in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01. In connection with the closing of the Merger, the Company (i) notified The Nasdaq Stock Market LLC ( Nasdaq ) that the Merger was consummated and (ii) requested that Nasdaq (A) halt trading of and delist the Common Shares effective before the opening of trading on January 7, 2026, and (B) file with the SEC a Form 25 Notification of Remo…
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Sep 18, 2026, 01:32 AM

    The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:34 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 12, 2026, 12:05 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 11, 2026, 12:02 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:54 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:54 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.